Cambridge’s PlaqueTec raises €4.2 million to advance precision medicine for cardiovascular disease
Source ↗
👁 0
💬 0
Cambridge-based PlaqueTec, a MedTech company specialising in intracoronary liquid biopsy to identify inflammatory drivers of cardiovascular disease (CVD), has raised €4.2 million ($5 million) in fresh funding. The oversubscribed financing round was funded entirely by the company’s existing investor base.
Martin Stapleton, Chairperson, PlaqueTec, commented, “The decision by our existing shareholders to reinvest, and to do so at a level that exceeded our target, speaks directly to their confidenc
Martin Stapleton, Chairperson, PlaqueTec, commented, “The decision by our existing shareholders to reinvest, and to do so at a level that exceeded our target, speaks directly to their confidenc
Comments (0)